U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Debrisoquine, poor metabolism of

MedGen UID:
332377
•Concept ID:
C1837156
•
Finding
Synonym: DEBRISOQUINE, POOR METABOLISM OF
 
OMIM®: 124030; 608902

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  

Professional guidelines

PubMed

Potential genetic causes of heterogeneity of treatment effects.
Goldstein DB, Need AC, Singh R, Sisodiya SM
Am J Med 2007 Apr;120(4 Suppl 1):S21-5. doi: 10.1016/j.amjmed.2007.02.004. PMID: 17403378
Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease.
Tanaka E
J Clin Pharm Ther 1998 Jun;23(3):161-70. doi: 10.1046/j.1365-2710.1998.00135.x. PMID: 9831966
A risk-benefit assessment of mirtazapine in the treatment of depression.
Kasper S, Praschak-Rieder N, Tauscher J, Wolf R
Drug Saf 1997 Oct;17(4):251-64. doi: 10.2165/00002018-199717040-00005. PMID: 9352961

Recent clinical studies

Etiology

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A, Dorado P, Peñas-Lledó EM
Pharmacogenomics 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. PMID: 19102711
Populations and genetic polymorphisms.
Weber WW
Mol Diagn 1999 Dec;4(4):299-307. doi: 10.154/MODI00400299. PMID: 10671640
Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look.
Tanner CM
Neurology 1991 May;41(5 Suppl 2):89-91; discussion 92. doi: 10.1212/wnl.41.5_suppl_2.89. PMID: 2041601
Liver enzyme abnormalities in Parkinson's disease.
Tanner CM
Geriatrics 1991 Aug;46 Suppl 1:60-3. PMID: 1894148
Polymorphic drug metabolism.
Relling MV
Clin Pharm 1989 Dec;8(12):852-63. PMID: 2689060

Diagnosis

Potential genetic causes of heterogeneity of treatment effects.
Goldstein DB, Need AC, Singh R, Sisodiya SM
Am J Med 2007 Apr;120(4 Suppl 1):S21-5. doi: 10.1016/j.amjmed.2007.02.004. PMID: 17403378
On the assessment of drug metabolism by assays of codeine and its main metabolites.
Haffen E, Paintaud G, Berard M, Masuyer C, Bechtel Y, Bechtel PR
Ther Drug Monit 2000 Jun;22(3):258-65. doi: 10.1097/00007691-200006000-00005. PMID: 10850391
Populations and genetic polymorphisms.
Weber WW
Mol Diagn 1999 Dec;4(4):299-307. doi: 10.154/MODI00400299. PMID: 10671640
Role of genetics and drug metabolism in human cancer risk.
Nebert DW
Mutat Res 1991 Apr;247(2):267-81. doi: 10.1016/0027-5107(91)90022-g. PMID: 2011144
The metabolism of glyburide in subjects of known debrisoquin phenotype.
Peart GF, Boutagy J, Shenfield GM
Clin Pharmacol Ther 1989 Mar;45(3):277-84. doi: 10.1038/clpt.1989.28. PMID: 2493353

Therapy

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A, Dorado P, Peñas-Lledó EM
Pharmacogenomics 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. PMID: 19102711
Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
Böttiger Y, Dostert P, Benedetti MS, Bani M, Fiorentini F, Casati M, Poggesti I, Alm C, Alvan G, Bertilsson L
Br J Clin Pharmacol 1996 Dec;42(6):707-11. doi: 10.1046/j.1365-2125.1996.00471.x. PMID: 8971425Free PMC Article
Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine.
Jedrychowski M, Feifel N, Bieck PR, Schmidt EK
J Pharm Biomed Anal 1993 Mar;11(3):251-5. doi: 10.1016/0731-7085(93)80205-f. PMID: 8518326
Amitriptyline-induced prolonged cholestasis.
Larrey D, Amouyal G, Pessayre D, Degott C, Danne O, Machayekhi JP, Feldmann G, Benhamou JP
Gastroenterology 1988 Jan;94(1):200-3. doi: 10.1016/0016-5085(88)90631-2. PMID: 3335290
Oxidation phenotype and the metabolism and action of beta-blockers.
Lennard MS
Klin Wochenschr 1985 Apr 1;63(7):285-92. doi: 10.1007/BF01731972. PMID: 2860267

Prognosis

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A, Dorado P, Peñas-Lledó EM
Pharmacogenomics 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. PMID: 19102711
Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.
Sachse C, Brockmöller J, Hildebrand M, Müller K, Roots I
Pharmacogenetics 1998 Apr;8(2):181-5. PMID: 10022755
Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA, Zanger UM
Annu Rev Pharmacol Toxicol 1997;37:269-96. doi: 10.1146/annurev.pharmtox.37.1.269. PMID: 9131254
Role of genetics and drug metabolism in human cancer risk.
Nebert DW
Mutat Res 1991 Apr;247(2):267-81. doi: 10.1016/0027-5107(91)90022-g. PMID: 2011144
Amitriptyline-induced prolonged cholestasis.
Larrey D, Amouyal G, Pessayre D, Degott C, Danne O, Machayekhi JP, Feldmann G, Benhamou JP
Gastroenterology 1988 Jan;94(1):200-3. doi: 10.1016/0016-5085(88)90631-2. PMID: 3335290

Clinical prediction guides

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
Llerena A, Dorado P, Peñas-Lledó EM
Pharmacogenomics 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. PMID: 19102711
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J, Skarke C, Liefhold J, Geisslinger G
Clin Pharmacokinet 2004;43(14):983-1013. doi: 10.2165/00003088-200443140-00003. PMID: 15530129
Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.
Sachse C, Brockmöller J, Hildebrand M, Müller K, Roots I
Pharmacogenetics 1998 Apr;8(2):181-5. PMID: 10022755
Molecular mechanisms of genetic polymorphisms of drug metabolism.
Meyer UA, Zanger UM
Annu Rev Pharmacol Toxicol 1997;37:269-96. doi: 10.1146/annurev.pharmtox.37.1.269. PMID: 9131254
Amitriptyline-induced prolonged cholestasis.
Larrey D, Amouyal G, Pessayre D, Degott C, Danne O, Machayekhi JP, Feldmann G, Benhamou JP
Gastroenterology 1988 Jan;94(1):200-3. doi: 10.1016/0016-5085(88)90631-2. PMID: 3335290

Supplemental Content

Table of contents

    Genetic Testing Registry

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...